Contact Us Today!


or Use Our Simple Online Form to Give Us Feedback

We welcome your comments and feedback. Please include contact information if you'd like a response.

Did you find this page helpful?

If you would like a response, please include your contact information.

<< Return to Search Results

Dean Eliott, M.D.

Photo of Dean Eliott, M.D.
Associate Director, Retina Service
Specialties: Retina
Macular Degeneration Unit
Phone Number: 617-573-3736
Fax: 617-573-3698
Location: Massachusetts Eye and Ear
243 Charles Street
Boston, MA 02114
Office Hours:
Location: Mass. Eye and Ear Retina Consultants
3 Woodland Road, Suite 210
Stoneham, MA 02180
Office Hours: 781-662-5520
Board Certification: Ophthalmology
Medical School Vanderbilt University School of Medicine
Residency Ophthalmology, Wilmer Ophthalmological Institute/Johns Hopkins Hospital
Fellowship Vitreoretinal Surgery, Duke University Medical Center
Teaching Affiliation Stelios Evangelos Gragoudas Associate Professor of Ophthalmology, Harvard Medical School
Biographical Profile:

Dr. Dean Eliott enjoys a national reputation as a gifted vitreoretinal surgeon and is sought by colleagues for difficult surgical cases. He has developed a focused translational research program that is dedicated toward developing novel approaches to combat retinal disease, particularly through clinical and translational research in diabetic retinopathy, age-related macular degeneration, and complex vitreoretinal surgical disorders. He also plays an important role training ophthalmology residents and fellows in the clinic and in the operating room, serving as Co-Director of Mass. Eye and Ear’s Vitrectomy Course and Retina Fellowship. 

Dr. Eliott attended Duke University as an undergraduate, moving on to Vanderbilt University School of Medicine. He then completed his ophthalmology residency at Wilmer/Johns Hopkins Hospital where he served as Chief Resident. This was followed by a vitreoretinal fellowship at Duke and six years on the faculty at Kresge Eye Institute in Detroit. Before coming to Mass. Eye and Ear, Dr. Eliott was Professor of Ophthalmology, Director of Clinical Affairs, and Director of Vitreoretinal Fellowship at the USC Keck School of Medicine’s Doheny Eye Institute in Los Angeles. 

As a clinical innovator and clinician scientist, Dr. Eliott has a particular interest in implantable and sustained-release steroid devices and vision-restoring electrical devices. Actively engaged in bringing new medications and devices from the bench to the bedside, he has a long history of research funding from both government and industry sources for clinical multicenter trials.
Dr. Eliott has been the recipient of several honors, including an American Academy of Ophthalmology Achievement Award, the Crystal Apple Award from the Young Physicians group of the American Society of Retina Specialists, and the Vitreous Society Honor Award. He also is a sought after regional, national and international speaker.

Research and Clinical Interests

Diabetic retinopathy, macular degeneration, retinal detachment, surgery for retina-vitreous disorders and ocular trauma


For a full publication list, please see his CV. A representative list (2006 - 2014) is available through

Yonekawa Y, Hacker HD, Lehman RE, Beal CJ, Veldman PB, Vyas NM, Shah AS, Wu D, Eliott D, Gardiner MF, Kuperwaser MC, Rosa RH Jr, Ramsey JE, Miller JW, Mazzoli RA, Lawrence MG, Arroyo JG. Ocular blast injuries in mass-casualty incidents: The marathon bombing in Boston, Massachusetts, and the fertilizer plant explosion in West, Texas. Ophthalmology. 2014 May 17. 

Channa R, Sophie R, Khwaja AA, Do DV, Hafiz G, Nguyen QD, Campochiaro PA; READ-2 Study Group. Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. Eye (Lond). 2014 Mar;28(3):269-78.

Gentile RC, Eliott D. Silicone oil retention sutures in aphakic eyes with iris loss. Arch Ophthalmol. 2010 Dec; 128(12): 1596-9.

VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006 Sep; 113 (9):1508.e1-25.

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5; 355(14): 1419-31.